Wolverine Trading, LLC Bristol Myers Squibb CO Put Options Transaction History

Wolverine Trading, LLC

$93.9 Billion
Q3 2024

Put Options

26 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$39.66 - $51.75 $5.1 Million - $6.65 Million	128,500 Added 39.3%	455,500 $23.6 Million
Q2 2024 Aug 14, 2024	BUY	$40.25 - $52.99 $3.3 Million - $4.35 Million	82,100 Added 33.52%	327,000 $13.6 Million
Q1 2024 May 15, 2024	BUY	$47.98 - $54.4 $1.57 Million - $1.78 Million	32,800 Added 15.46%	244,900 $13.3 Million
Q4 2023 Feb 14, 2024	SELL	$48.48 - $57.85 $2.01 Million - $2.39 Million	-41,400 Reduced 16.33%	212,100 $10.9 Million
Q3 2023 Nov 15, 2023	SELL	$57.89 - $64.73 $966,763 - $1.08 Million	-16,700 Reduced 6.18%	253,500 $14.7 Million
Q2 2023 Aug 23, 2023	BUY	$63.71 - $70.74 $17.2 Million - $19.1 Million	270,200 New	270,200 $17.3 Million
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $3,926 - $2.32 Million	-30,200 Reduced 6.4%	441,600 $31.7 Million
Q2 2022 Aug 15, 2022	BUY	$72.62 - $79.98 $3.73 Million - $4.11 Million	51,400 Added 12.23%	471,800 $36.9 Million
Q1 2022 May 16, 2022	BUY	$61.48 - $73.72 $2.86 Million - $3.43 Million	46,500 Added 12.44%	420,400 $31 Million
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $970,703 - $1.13 Million	-18,100 Reduced 4.62%	373,900 $23.4 Million
Q3 2021 Nov 12, 2021	BUY	$59.17 - $69.31 $3.24 Million - $3.8 Million	54,800 Added 16.25%	392,000 $23.8 Million
Q2 2021 Aug 06, 2021	BUY	$61.91 - $67.42 $2.43 Million - $2.64 Million	39,200 Added 13.15%	337,200 $22.3 Million
Q1 2021 May 14, 2021	SELL	$59.34 - $66.74 $450,984 - $507,223	-7,600 Reduced 2.49%	298,000 $18.9 Million
Q4 2020 Feb 12, 2021	BUY	$57.74 - $65.43 $4.09 Million - $4.64 Million	70,900 Added 30.21%	305,600 $18.9 Million
Q3 2020 Nov 13, 2020	SELL	$57.43 - $63.64 $648,959 - $719,132	-11,300 Reduced 4.59%	234,700 $14.1 Million
Q2 2020 Aug 13, 2020	SELL	$54.82 - $64.09 $5.79 Million - $6.77 Million	-105,600 Reduced 30.03%	246,000 $14.2 Million
Q1 2020 May 11, 2020	SELL	$46.4 - $67.43 $11.5 Million - $16.8 Million	-248,500 Reduced 41.41%	351,600 $19.1 Million
Q4 2019 Feb 12, 2020	BUY	$49.21 - $64.19 $9.5 Million - $12.4 Million	193,100 Added 47.44%	600,100 $38.2 Million
Q3 2019 Nov 14, 2019	SELL	$42.77 - $50.71 $1.95 Million - $2.31 Million	-45,500 Reduced 10.06%	407,000 $20.4 Million
Q2 2019 Aug 20, 2019	SELL	$44.62 - $49.34 $16.1 Million - $17.8 Million	-360,800 Reduced 44.36%	452,500 $20.5 Million
Q1 2019 May 15, 2019	BUY	$45.12 - $53.8 $18 Million - $21.5 Million	398,800 Added 96.21%	813,300 $38.8 Million
Q4 2018 Feb 14, 2019	BUY	$48.76 - $63.23 $9.45 Million - $12.3 Million	193,800 Added 87.81%	414,500 $21.1 Million
Q3 2018 Nov 14, 2018	BUY	$55.19 - $62.25 $66,228 - $74,700	1,200 Added 0.55%	220,700 $13.7 Million
Q1 2018 May 15, 2018	SELL	$59.92 - $68.98 $6.82 Million - $7.86 Million	-113,900 Reduced 34.16%	219,500 $13.9 Million
Q4 2017 Feb 14, 2018	BUY	$59.94 - $65.35 $4.35 Million - $4.74 Million	72,500 Added 27.79%	333,400 $20.4 Million
Q3 2017 Nov 15, 2017	BUY	$55.23 - $63.74 $14.4 Million - $16.6 Million	260,900	260,900 $16.6 Million

Others Institutions Holding BMY

# of Institutions

2,533

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

Vanguard Group Inc Valley Forge, PA

189M
Shares

$11.1 Billion
0.18% of portfolio
Black Rock Inc. New York, NY

159M
Shares

$9.34 Billion
0.15% of portfolio
State Street Corp Boston, MA

92.9M
Shares

$5.47 Billion
0.2% of portfolio
Jpmorgan Chase & CO New York, NY

77.9M
Shares

$4.59 Billion
0.33% of portfolio
Charles Schwab Investment Management Inc San Francisco, CA

61M
Shares

$3.59 Billion
0.61% of portfolio

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $125B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.

Account